Randomized controlled trials in schizophrenia: Opportunities, limitations, and trial design alternatives

Dialogues in Clinical Neuroscience

Volumn 13, Issue 2, 2011, Pages 155-172

  Correll, Christoph U ^a   Kishimoto, Taishiro ^b   Kane, John M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Conduct; Design; Implementation; Methodology; Placebo response; Randomized controlled trial; Rater bias; Statistics

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; PLACEBO; NEUROLEPTIC AGENT;

ARTICLE; COMORBIDITY; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL DISEASE; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PERSONALIZED MEDICINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; DOUBLE BLIND PROCEDURE; REPRODUCIBILITY; REVIEW; STANDARD;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 80052149754     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. World Health Organization. International Statistical Classification of Diseases, Injuries, and Causes of Death. Sixth Revision of the International Lists of Diseases and Causes of Death. 1949.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 1952.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 1980.
4. Klein DF, Davis JM Diagnosis and Drug Treatment of Psychiatric Disorders. 1969.
5. Griffith RW, Saameli K Clozapine and agranulocytosis. Lancet. 1975;2:657.
6. Kane J.M, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
7. Essali A, Al-Haj Haasan N, Li C, Rathbone J Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;1:CD000059.
8. Meltzer HY, Alphs L, Green AI, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:735.
9. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of headto-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
10. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;11:CD006633.
11. Kane JM, Quitkin F, Rifkin A, Ramos-Lorenzi JR, Nayak DV Fluphenazine versus placebo in patients with remitted acute first episode schizophrenia. Arch Gen Psychiatry. 1982;39:70-73.
12. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
13. Melle I, Larsen TK, Haahr U, Friis S, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008;65:634-640.
14. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559.
15. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff Dl, Geisler SH, Szymanski SR Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149:1183-1188.
16. Robinson DG, Woerner MG, Delman HM, Kane JM Pharmacological treatments for first-episode schizophrenia. Schizophr Bull. 2005;31:705-722.
17. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
18. Correll CU, Kratochvil CJ, March J Developments in pediatric psychopharmacology: focus on stimulants, antidepressants and antipsychotics. J Clin Psychiatry.
19. Kane JM, Correll CU Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115-1124.
20. Rosenheck R, Perlick D, Bingham S, et al. Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;26;290:2693-2702.
21. Liebennan JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
22. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
23. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Ain J Psychiatry. 2009;166:152-163.
24. McEvoy JP, Lieberman JA, Stroup TS, et al., CATIE Investigators Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypicalantipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
25. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185-194.
26. Newcomer JW Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 (suppl 1):1-93.
27. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69:514-519.
28. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scancl. 2007;116:317-333.
29. Colton CW, Manderscheid RW Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.
30. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparites in health care. World Psychiatry. 2011;10:1052-1077.
31. Ray WA, Chung CP, Murray KT, Hall K, Stein CM Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-35. 2009;361:1814.
32. Correll CU, Nielsen J Antipsychotic-associated ail-cause and cardiac mortality: what should we worry about and how should the risk be assessed? Acta Psychiatr Scand. 2010;122:341-344.
33. Schneider LS, Dagerman KS, Insel P Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
34. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K First, vs. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192:406-411.
35. Nielsen J, Skadhede S, Correll CU Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35:1997-2004.
36. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.
37. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
38. Kane JM, Leucht S Unanswered questions in schizophrenia clinical trials. Schizophr Bull. 2008;34:302-309.
39. Leucht S, Heres S, Hamann J, Kane JM Methodological issues in current antipsychotic drug trials. Schizophr Bull. 2008;34:275-285.
40. Liberman RP, Kopelowicz A, Ventura J, Gutkind D Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14:256-272.
41. Naber D, Karow A, Lambert M Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl. 2005;427:29-34.
42. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690-1697.
43. Green MF, Penn DL, Bentall R, Carpenter WT, et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. 2008;34:1211-1220.
44. Harvey PD, Green MF, Bowie C, Loebel A The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. Psyche/pharmacology (Berf). 2006;187:356-363.
45. Keefe RS, Vinogradov S, Medalia A, et al. Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia. Schizophr Bull. 2010 [Epub ahead of print].
46. Lehman AF, Goldberg R, Dixon LB, et al. Improving employment outcomes for persons with severe mental illnesses. Arch Gen Psychiatry. 2002;59:165-172.
47. McGurk SR, Schiano D, Mueser KT, Wolfe R Implementation of the thinking skills for work program in a psychosocial clubhouse. Psychiatr Rehabil J. 2010;33:190-199.
48. Evans JD, Bond GR, Meyer PS, et al. Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. Schizophr Res. 2004;70:331-342.
49. Correll CU, Canas F, Larmo I, et al. Individualizing antipsychotic treatment selection in schizophrenia: characteristics of empirically derived patient subgroups. Eur Psychiatry. 2011;26 (suppl 1):3-16.
50. Falkai P, Mike O, Inez MG, Paul H, Andras BG, Sophia F, MEOS Consortium A roadmap to disentangle the molecular etiology of schizophrenia. Eur Psychiatry. 2008;23:224-232.
51. Lathia CD, Amakye D, Dai W, et al. The value, qualification, and regulatory use of surrogate end points in drug development. Clin Pharmacol Ther. 2009;86:32-43.
52. Agid O, Foussias G, Singh S, Remington G Where to position clozapine: re-examining the evidence. Can J Psychiatry. 2010;55:677-684.
53. Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011. [Epub ahead of print].
54. Robinson D, Woerner MG, Pollack S, Lerner G Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. J Clin Psychopharmacol. 1996;16:170-176.
55. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000;20:699-702.
56. Salimi K, Jarskog LF, Lieberman JA Antipsychotic drugs for first episode schizophrenia: a comparative review. CNS Drugs. 2009;23:837-855.
57. Agid O, Kapur S, Arenovich T, Zipursky RB Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228-1235.
58. Leucht S, Busch R, Hamann J, Kissling W, Kane JM Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57:1543-1549.
59. Leucht S, Busch R, Kissling W, Kane JM Early prediction of antipsychotic non-response. J Clin Psychiatry. 2007;68:352-360.
60. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230-240.
61. Kinon BJ, C, Ascher-Svanum H, Stauffer VL, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacol. 2010;35:581-590.
62. Correll CU From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics, Eur Psychiatry. 2010;25 Suppl 2:512-521.
63. Meltzer HY Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep. 2002;4:279-283.
64. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50:792-801.
65. Marks DM, J T, Pae CU Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches. Psychiatry investig. 2009;6:1-6.
66. Kane JM, Rifkin A, Quitkin F, et al. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Res. 1979; 1:341-348.
67. World Medical Association (WMA). Declaration of Helsinki-Ethical principles for medical research involving human subjects, Adopted by the 18Th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 59th WMA General Assembly, Seoul, October 2008.
68. Fleischhacker WW, Burns T European Group For Research In Schizophrenia. Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe. Psyche/pharmacology. 2002;162:82-84.
69. Hummer M, Holzmeister R, Kemmler G, et al. Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry. 2003;64:277-281.
70. Roberts LW The ethical basis of psychiatric research: conceptual issues and empirical findings. Comp Psychiatry.;39:99-110.
71. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62:1305-1312.
72. Kemp AS, Schooler NR, KalaIi AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36:504-509.
73. Loebel A, Cucchairo J, Siu C, Daniel D, et al. Signal detection in clinical trials: A post-study survey of schizophrenia trial sites. Paper presented at: ISCTM 2010 Autumn Conference, 13-14 October. Baltimore, MD.
74. Chen Y-F, Wang S-J, Khin NA, Hung MJ, et al. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharmaceutical Statistics. 2010;9:217-229.
75. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70:1348-1357.
76. Emsley R, Rabinowitz J, Medori R Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006;163:743-745.
77. Gallego JA, Robinson DG, Sevy SM, et al. Time to treatment response in first episode schizophrenia: must acute treatment trials last several months? J Clin Psychopharmacol. In press.
78. Agid O, Kapur S, Warrington L, Loebel A, Siu C Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res. 2008;102:241-248.
79. Papanikolaou PN, Churchill R, Wahlbeck K, loannidis JP Safety reporting in randomized trials of mental health interventions. Am J Psychiatry. 2004;161:1692-1697.
80. Kobak KA, Brown B, Sharp I, Levy-Mack H, Wells K, Ockun F, Williams JB Sources of unreliability in depression ratings. J Clin Psychopharmacol. 2009;29:82-5. 2009;29:221.
81. Kobak KA Feiger AD. Lipsitz JD. Interview quality and signal detection in clinical trials. Am J Psychiatry. 2005;162:628.
82. Kobak KA, Leuchter A, DeBrota D, et al. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacology. 2010;30:193-197.
83. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222.
84. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83-92.
85. Woods SW, Gueorguieva RV, Baker CB, Makuch RW Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry. 2005;62:961-970.
86. Rosenheck RA, Krystal. JH, Lew R, et al for the CSP555 Research Group Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364:842-51.
87. Li R, Zhang M, Shi S The effect of haloperidol decanoate on negative and positive symptoms of schizophrenia. Chin J Nerv Ment Diseases. 1996;22:9-12.
88. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35:2367-77.
89. Csernansky JG, Mahmoud R, Brenner R A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002; 346:16-22.
90. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947-953.
91. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry. 1983;40:893-896.
92. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002;159:554-560.
93. Leon AC Implications of clinical trial design on sample size requirements. Schizophr Bull. 2008;34:664-669.
94. Leon AC, Demirtas H, Hedeker D Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial. Clin Trials. 2007;4:540-547.
95. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S Dropout rates in randomized antipsychotic drug trials. Psychopharmacology (Berl). 2001;155:230-233.
96. Nedopil N, Pflieger R, Ruther E The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Phannacopsychiatria. 1983;16:201-205.
97. Bartko G, Herczeg I, Bekesy M Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J Clin Psychiatry. 1987;48:363-365.
98. Awad AG, Voruganti LN Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand. Suppl. 2005;427:6-13.
99. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005;162:939-946.
100. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2005;162:1774.
101. Chang YC, Lane HY, Yang KH, Huang CL Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol. 2006;26:554-559.
102. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34:1163-1171.
103. Kay SR, Fiszbein A, Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
104. Overall JE, Gorham DR The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
105. Ruberg SJ, Chen LL, Stauffer V, et al. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2011;11:23.
106. Stauffer VL Case M. Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011;187:42-48.
107. Levine SZ, Rabinowitz J Trajectories and antecedents of treatment response overtime in early-episode psychosis. Schizophr Bull. 2010;36:624-632.
108. Levine SZ Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010;68:86-92.
109. Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H Treatment response trajectories and their antecedents in recent-onset psychosis: a 2year prospective study. J Clin Psychopharmacol. 2010;30:446-449.
110. Marques TR, Arenovich T, Agid O, et al. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med. 2010. [Epub ahead of print].
111. Fava M, Evins AE, Dorer DJ, Schoenfeld DA The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115-127.